Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

20 June 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Pixuvri Articles

Germany's G-BA issues final assessment for Cell Thera's Pixuvri

21 May 2013

Positive NICE recommendation for Novartis' Lucentis, but not for Cell Thera's Pixuvri

11 April 2013

Germany's IQWiG finds no added benefit for Komboglyze or for Pixuvri

4 March 2013

Cell Therapeutics initiates launch of Pixuvri in Europe

12 September 2012

Cell Therapeutics prepares for Pixuvri launch; posts 2nd-qtr results

1 August 2012

Cell Therapeutics prepares for EU launch of Pixuvri

21 June 2012

Cell Therapeutics' Pixuvri cleared in EU for NHL

14 May 2012

EMA turns positive on orlistat and aprotinin; CHMP backs Pixuvri

20 February 2012

Cell Therapeutics updates on Pixuvri

30 January 2012

FDA advisory to review Cell Thera’s re-submitted pixantrone NDA

3 January 2012

EMEA validates Cell Therapeutics’ expanded pixantrone PIP

17 August 2010

Italian medicines agency OKs NerPharMa facility to make Cell Therapeutics' pixantrone in EU

16 June 2010

US FDA calls for more info on Cell Thera’s pixantrone NDA, and firm says it will file for expanded access for NHL patients

9 April 2010

Showing 1-13 of 13 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
  • US Supreme Court says patent settlement can "sometimes" be illegal
  • Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
  • FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
  • Australia's pharma industry applauds R&D regulatory reform
  • Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
  • US Supreme Court says patent settlement can "sometimes" be illegal
  • Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
  • FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
  • Australia's pharma industry applauds R&D regulatory reform

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS